AMGEN USA INC

EXERCISE OPTION PERIOD 3 CLINS 0010, 0011, AND 0012.

DE-OBLIGATE FUNDING FOR CONTRACT CLOSEOUT.

TAVNEOS (AVACOPAN)

EXERCISE OPTION PERIOD 2 CLINS 0007 - 0009 FOR THE PROCUREMENT OF 62,896 UNITS OF NPLATE PHARMACEUTICAL PRODUCTS.

EXERCISE OPTIONAL CLIN 0004 (FAR 52.217-8 OPTION TO EXTEND SERVICES) AND EXTEND THE PERIOD OF PERFORMANCE UNTIL 16 DECEMBER 2024.

VENDOR MANAGED INVENTORY (VMI) SERVICES FOR USG PROCURED 165,906 DOSES OF NEULASTA PRODUCT TO MITIGATE INJURIES CAUSED BY EXPOSURE TO CHEMICAL, BIOLOGICAL THREAT AGENTS, PHYSICAL, RADIOLOGIC AND NUCLEAR EXPOSURES.

TAVNEOS (AVACOPAN)

AMGEN - EXERCISE OPTIONAL CLINS 0004, 0005, AND 0006. ADD FAR CLAUSE 52.204-27.

INVOKE FAR CLAUSE 52.217-8, PROVIDE FUNDING IN THE AMOUNT OF $49,520.38 FOR CLINS 0001, INCORPORATE FAR CLAUSES 52.204-27 AND HHSAR CLAUSE 352.232-71.

EXERCISE FAR CLAUSE 52.217-8, ADD FAR CLAUSE 52.204-27 AND HHSAR CLAUSE 352.232-71, REVISE SECTION G.7 INVOICE SUBMISSION, AND REVISING THE CONTRACTING OFFICER.

TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.